1-3 of 3
Jeannette van der Giessen, BA, CCRP
Close
Sort by
Journal Articles

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Weili Sun, MDPhD, Paul S Gaynon, MD, Richard Sposto, PhD, Henrique Bittencourt, MD, Andrew E. Place, MDPhD, Yoav H Messinger, MD, Chris Fraser, MD, Luciano Dalla-Pozza, MD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Xiaojing Yang, PhD, Gangning Liang, PhD, Peter A. Jones, PhD DSc, Alan S. Wayne, MD, Todd Cooper, DO
Journal: Blood
Blood (2014) 124 (21): 3764.
https://doi.org/10.1182/blood.V124.21.3764.3764
Published: 2014
Journal Articles

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Yoav H Messinger, MD, Paul Gaynon, MD, Richard Sposto, Ph.D., Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Jemily Malvar, M.S., Bruce C. Bostrom, MD
Journal: Blood
Blood (2011) 118 (21): 251.
https://doi.org/10.1182/blood.V118.21.251.251
Published: 2011
Journal Articles

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Yoav H. Messinger, MD, Paul S. Gaynon, MD, Elizabeth Raetz, MD, Raymond Hutchinson, MD, MS, Steven DuBois, MD, Julia Glade Bender, MD, Richard Sposto, PhD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Bruce C. Bostrom, MD
Journal: Blood
Blood (2008) 112 (11): 1919.
https://doi.org/10.1182/blood.V112.11.1919.1919
Published: 2008